EDAP TMS S.A., each representing One Ordinary Share (EDAP) Company Bio
EDAP TMS S.A. develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company was founded in 1979 and is based in Vaulx-en-Velin, France.
EDAP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Edap Tms Sa with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Edap Tms Sa ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 35.33%. As for the metrics that stood out in our discounted cash flow analysis of Edap Tms Sa, consider:
The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately only 17.54% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Edap Tms Sa? See NVS, CAH, GILD, LMAT, and OSMT.
EDAP (EDAP) is surviving the drought of hospitals buying new stuff as a result of the pandemic being quite a bit better than many would have thought, which is why their share price has recovered nicely after encouraging Q2 results: We wrote in October last year that the company was...
Shareholders Unite on Seeking Alpha | September 16, 2020
Call to be Held Tuesday, September 22nd @ 8am Eastern TimeLYON, France, September 15, 2020 \-- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One® and ExactVu™, on Tuesday, September 22nd at 8am Eastern Time.The call will feature a presentation by Key Opinion Leaders (KOL) Brian Miles, MD (Houston Methodist) and Laurence Klotz, MD (Sunnybrook Health Sciences Centre) who will discuss the opportunity for the Focal One® High Intensity Focused Ultrasound (HIFU) system and the ExactVu™ micro-ultrasound. Drs. Miles and Klotz will be available to answer questions at the conclusion of the call.EDAP TMS's management team will also give an update o...
LYON, France, September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held September 14-15, 2020. Presentation details Date: Tuesday, September 15 Time: 10:30am EDT Webcast: https://wsw.com/webcast/hcw7/edap/1581034The webcast will be archived and available for replay for a period of 90 days.About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modaliti...
· First patients already treated as recruitment acceleratesLYON, France, September 3, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Follow-up of these patients will evaluate the safety and efficacy of HIFU for this pathology. Additional patients continue to be enrolled.Pr. Gil Dubernard, Head of the Gynecologic Department, Croix-Rousse University Hospital, Lyon, and lead investigator, commented, ...
* Completed multiple Focal One sales to renowned U.S. and international health care institutions, including multiple Focal One™-ExactVu™ bundled sales * Announced first two U.S. publications in Journal of Urology detailing positive outcomes from U.S. studies of HIFU for the successful partial-gland ablation of prostate tissue * Maintained a strong cash position of EUR 15.7 million (USD 17.7 million) as of June 30, 2020 * Company to host a conference call tomorrow, August 27th, at 8:30 am EDT LYON, France, August 26, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the second quarter of 2020 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP's Chairm...